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Abstract
Background: Effective treatment remains a mainstay of malaria control, but it is unfortunately strongly compromised 
by drug resistance, particularly in Plasmodium falciparum, the most important human malaria parasite. Although P. 
falciparum chemoresistance is well recognized all over the world, limited data are available on the distribution and 
prevalence of pfcrt and pfmdr1 haplotypes that mediate resistance to commonly used drugs and that show distinct 
geographic differences.
Methods: Plasmodium falciparum-infected blood samples collected in 2007 at four municipalities of Luanda, Angola, 
were genotyped using PCR and direct DNA sequencing. Single nucleotide polymorphisms in the P. falciparum pfcrt and 
pfmdr1 genes were assessed and haplotype prevalences were determined.
Results and Discussion: The most prevalent pfcrt haplotype was StctVMNT (representing amino acids at codons 72-
76). This result was unexpected, since the StctVMNT haplotype has previously been seen mainly in parasites from South 
America and India. The CVIET, CVMNT and CVINT drug-resistance haplotypes were also found, and one previously 
undescribed haplotype (CVMDT) was detected. Regarding pfmdr1, the most prevalent haplotype was YEYSNVD 
(representing amino acids at codons 86, 130, 184, 1034, 1042, 1109 and 1246). Wild haplotypes for pfcrt and pfmdr1 
were uncommon; 3% of field isolates harbored wild type pfcrt (CVMNK), whereas 21% had wild type pfmdr1 (NEYSNVD). 
The observed predominance of the StctVMNT haplotype in Angola could be a result of frequent travel between Brazil 
and Angola citizens in the context of selective pressure of heavy CQ use.
Conclusions: The high prevalence of the pfcrt SVMNT haplotype and the pfmdr1 86Y mutation confirm high-level 
chloroquine resistance and might suggest reduced efficacy of amodiaquine in Angola. Further studies must be 
encouraged to examine the in vitro sensitivity of pfcrt SVMNT parasites to artesunate and amodiaquine for better 
conclusive data.
Background
More than 125 years after the discovery of the causative
parasites, malaria continues to be one of the most impor-
tant infectious diseases in the world. According to WHO,
3.3 billion people are at risk, and about 250 million
malaria cases occur annually, causing nearly one million
deaths, mostly in children below five years of age. Overall,
109 countries are endemic for malaria; 45 of these are in
Africa [1]. While work continues toward a malaria vac-
cine, prompt diagnosis and effective treatment remain, in
addition to vector control measures, mainstays of malaria
control [2]. Unfortunately, disease control is strongly
compromised by the emergence of resistance to com-
monly used drugs [3]. Of particular concern is resistance
in  Plasmodium falciparum, the most virulent human
malaria parasite [4].
Important advances in the understanding of mecha-
nisms of anti-malarial drug resistance have been made in
recent years [5]. Resistance to chloroquine (CQ), which
was previously the most widely used anti-malarial, is
mainly conferred by single-nucleotide polymorphisms
(SNPs) in pfcrt, a putative transmembrane transporter
localized in the parasite digestive vacuole membrane [6].
In particular, the pfcrt K76T mutation plays a central role
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in mediating resistance to CQ, and it is considered a reli-
able molecular marker of resistance [7,8]. Polymorphisms
in another gene, pfmdr1, are associated with modulation
of parasite susceptibility to a number of drugs, including
CQ and amodiaquine [9].
Regarding the pfcrt gene, a haplotype defined by the
K76T codon and adjacent amino acids (numbers 72-75)
has been used to type malaria parasites. Three main pfcrt
haplotypes have been identified [10]: CVMNK among
CQ-sensitive isolates from all geographic regions, CVIET
among CQ-resistant isolates from Southeast Asia and
Africa, and SVMNT among CQ-resistant isolates from
South America (type StctVMNT; the subscript represents
codon usage) and some countries of Asia (type Sagt-
VMNT) [11-15].
Although  P. falciparum chemoresistance has been
described in most malarious regions [5], limited data are
available on the distribution and prevalence of pfcrt and
pfmdr1 haplotypes. It was investigated the prevalence of
mutations in these two genes in P. falciparum from
Angola, where only two such molecular studies have been
published previously [16,17].
Methods
Study site and population
Clinical samples were collected in 2007 at Luanda, the
capital of Angola, from individuals living in the munici-
palities of Sambizanga, Imgombotas, Cazenga and Viana.
Luanda has a population of approximately 4.5 million and
is considered a meso-endemic malaria area, according to
parasitological surveys in children < 5 years and number
of malaria deaths at local hospitals. Malaria is present
throughout the year, with a marked increase after rains
peak during April and May [18]. The treatment policy in
Angola for uncomplicated falciparum malaria in absence
of first trimester of pregnancy included artemether +
lumefantrine or alternatively artesunate + amodiaquine.
Patients diagnosed with falciparum malaria based on
Giemsa-stained thick smear were included in this study,
after obtaining informed consent. Inclusion criteria were
individuals with age ≥ 18 years, uncomplicated malaria,
monoinfection with P. falciparum and unaware of first
trimester pregnancy. The study was approved by the
National Institute of Public Health/Angola Ethics
Research Committee with concurrence from the Instituto
Oswaldo Cruz/Fiocruz.
Study procedures
After enrollment, 5 ml of blood was collected by veni-
puncture and placed into ethylenediaminetetraacetic acid
(EDTA) vacutainer tubes (Becton Dickinson). The sam-
ples were centrifuged (350 g, 10 minutes), pellets were
frozen with an equal volume of cryopreservation solution
(0.9% sodium chloride, 4.2% sorbitol and 28% glycerol)
and transported frozen to the Instituto Oswaldo Cruz
(Fiocruz), Rio de Janeiro, Brazil.
DNA preparation
Blood samples were thawed, and 1 ml was used for DNA
extraction with the QIAamp midi kit, as described by the
manufacturer (Qiagen). Samples were resuspended in a
final volume of 50 μl.
Nested PCR for pfcrt amplification
The pfcrt amplification protocol was described elsewhere
[19]. Briefly, 5 μl of DNA solution was added to a 45 μl
mixture containing 10 pmol of primers CRTP1 (5' CCG
TTA ATA ATA AAT ACA CGC AG 3') and CRTP2 (5'
CGG ATG TTA CAA AAC TAT AGT TAC C 3'). In a
subsequent PCR, 5 μl of the initial PCR product was
mixed with 10 pmol of primers CRTD1 (5' TGT GCT
CAT GTG TTT AAA CTT 3') and CRTD2 (5' CAA AAC
TAT AGT TAC CAA TTT TG 3'), to amplify a 134 bp
fragment comprising the pfcrt SNPs C72S, M74I, N75E/
D  and K76T. PCR reactions were run twice with the
GeneAmp PCR System 9700 (Applied Biosystems). DNA
positive and negative controls were also used in each
round of amplification. The positive control consisted of
DNA from blood samples from patients diagnosed with
falciparum malaria based on Giemsa-stained thick smear
and the negative control consisted of DNA from blood
samples of individuals without history of visiting endemic
areas as well as a blank tube without DNA.
Single PCRs for pfmdr1 amplification
Pfmdr1 gene analysis was performed with two PCR reac-
tions that were made two times using 3 μl of DNA solu-
tion in a 47 μl mixture containing 2.5 mM of MgCl2, 250
μM of dNTPs, 2.5 units of Amplitaq Gold® DNA poly-
merase (Applied Biosystems), and 10 pmol of primers
MDR1STF (5' CCG TTT AAA TGT TTA CCT GCA C
3') and MDR1STR (5' TTG CAA CAG TTC TTA TTC
CCA 3') to amplify a 604 bp region comprising SNPs
N86Y, E130K  and Y184F; or primers MDR1ENDF (5'
GCG GAG TTT TGC ATT TAG TTC 3') and
MDR1ENDR (5' CAA TGT TGC ATC TTC TCT TCC A
3') to amplify a 935 bp region comprising SNPs S1034C,
N1042D, V1109I  and D1246Y. The first reaction was
incubated at 95°C for 10 minutes, followed by 45 cycles
(94°C/1 minute, 58°C/1 minute and 72°C/1 minute) plus
one final incubation at 72°C for 10 minutes. The second
reaction was incubated at 95°C for 10 minutes, followed
by 45 cycles (94°C/1 minute and 30 seconds, 60°C/1 min-
ute and 30 seconds and 72°C/1 minute and 30 seconds)
and a final incubation at 72°C for 10 minutes. As for pfcrt
PCR, it was also used DNA positive and negative controls
in each PCR.Gama et al. Malaria Journal 2010, 9:174
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PCR analysis and product purification
PCR products were separated by 2% agarose-gel electro-
phoresis. Products were purified through the Wizard SV
Gel and PCR Clean-Up System (Promega), according to
the manufacturer's instructions.
Sequencing
DNA sequencing was performed using pfcrt  nested or
pfmdr1  single PCR primers plus the purified product
according to Big Dye®  Terminator Cycle Sequencing
Ready Reaction version 3.1 instructions (Applied Biosys-
tems). Sequences were read using an ABI PRISM DNA
Analyzer 3730 (Applied Biosystems) from the Genomic
Platform/PDTIS/Fiocruz [20].
Sequence analysis
The forward and reverse sequences were analysed using
the free software Bioedit Sequence Alignment Editor ver-
sion 7.0.5.2.
Results
DNA blood samples from 114 patients with uncompli-
cated falciparum malaria were tested. The majority of
samples were composed by adults with 21 to 30 years and
their parasitemia range was 500-100,000 parasites/μl. We
detected 102 PCR-positive samples for pfcrt  (32 from
Sambizanga, 42 from Ingombotas, 21 from Cazenga and
7 from Viana) and 28 samples for both pfmdr1  PCR
amplifications (5 from Sambizanga, 13 from Ingombotas,
6 from Cazenga and 4 from Viana). Frequent failures to
amplify pfmdr1 might be attributed to primer limitations
due to polymorphisms in target sequences; for all these
samples fragments were amplified using other primers
developed for diagnosis, confirming the presence of para-
site DNA in the samples [21].
Mixed infections with two different pfcrt  genotypes
were common (Table 1). The most prevalent haplotype
for pfcrt was StctVMNT (58/102). This result was unex-
pected, since the StctVMNT  haplotype has previously
been seen mainly in parasites from South America and
India [22,23]. The CVIET, CVMNT and CVINT drug-
resistance haplotypes were also found, and one previously
undescribed haplotype (CVMDT) was detected. Regard-
ing pfmdr1, the most prevalent haplotype was YEYSNVD
(17/28) (representing amino acids at positions 86, 130,
184, 1034, 1042, 1109 and 1246) with wild type sequence
except for the 86 codon (Table 2). No significant differ-
ence between the four municipalities was observed for
both genes.
Wild haplotypes for pfcrt and pfmdr1 were uncommon;
3% (3/102) of field isolates harbored wild type pfcrt
(CVMNK), whereas 21% (6/28) had wild type pfmdr1
(NEYSNVD). The co-analysis of pfcrt and pfmdr1 genes
(n = 28) revealed some prevalent pfcrt and pfmdr1 associ-
ations: pfcrt CVIET coexisted with pfmdr1 YEYSNVD in
29% of samples, StctVMNT  with  YEYSNVD in 14% of
samples and CVIET with NEYSNVD in 11% of samples.
Only one sample, from Imgombotas, was entirely wild
type in the pfcrt and pfmdr1 genes, and three samples,
from Cazenga and Imgombotas, harbored only one
mutation, this at pfmdr1 codon 184.
Discussion
In this study, the pfcrt and pfmdr1 haplotypes of P. falci-
parum from Angola (Luanda) were characterized. Well-
known as well as unusual pfcrt haplotypes were identi-
fied: CVMNK representing the sensitive haplotype, Stct-
VMNT, CVMNT, CVINT  and CVIET  representing
previously described drug-resistance-mediating haplo-
types, and CVMDT, a previously undescribed haplotype.
These results offer insight into the spread of drug resis-
tance in malaria parasites.
CQ-resistant P. falciparum parasites were first detected
in the 1950 s on the Thailand-Cambodia border and in
South America [24]. In Africa, resistant parasites are
thought to have originated from Southeast-Asian isolates
that spread progressively in the 1970 s through the Indian
subcontinent and then to East Africa. Different origins of
chloroquine resistance are supported by the existence of
different haplotypes in different areas, notably CVMNK
among CQ-sensitive isolates from all regions, and, among
resistance-mediating haplotypes CVIET  in Southeast
Asia and Africa, StctVMNT in South America, and Sagt-
VMNT in some countries of Asia [11-15].
Surprisingly, in this study the most prevalent pfcrt hap-
lotype was StctVMNT. In prior studies, this StctVMNT
allele was the predominant haplotype in Brazil [25], and it
has also been described in Guyana [26,27] and Peru [28].
It has been reported only once in Africa, in 4% of P. falci-
parum samples from Ghana [26]. In addition, an SVMNT
haplotype with different codon preference (SagtVMNT)
was seen in 19% of samples from Tanzania [, personal
communication, Michael Alifrangis]. The observed pre-
dominance of the StctVMNT haplotype in Angola could
b e  a  r e s u l t  o f  f r e q u e n t  t r a v e l s  b e t w e e n  B r a z i l i a n  a n d
Angolan citizens by means of trade, business and educa-
tional purposes, in the context of the selective pressure of
heavy use of CQ. It is important to remark that Angola
and Brazil have a singular relationship towards each
other. Since 2000, commerce between these two coun-
tries was established and it is now flourishing. With trade
enhancement, the presence of Brazilian companies in
Angola has grown and consequently, short or long-terms
travels from Brazil to Angola and vice-versa have also
increased. An analysis of neutral microsatellite markers
could help to explain if the high prevalence of the Stct-
VMNT haplotype in Angola is related to a Brazilian geo-Gama et al. Malaria Journal 2010, 9:174
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graphical allelic exchange or to a novel selection of
resistance in Angola [26,30]. Likewise, the pfcrt C/S VIET
mixed haplotype seen in Angola could give rise to the
SVIET haplotype previously identified in the Democratic
Republic of Congo [31]. Similar to potential transfer from
Brazil to Angola, the presence of this haplotype in Angola
might be due to traffic between the Democratic Republic
of Congo and Angola. In fact, there is an expressive non-
controlled migration from Congo to Angola mainly to
find work at diamond mines and in a lesser extend from
Angola to Congo to visit family members that were
moved to Congo due to colonial Portuguese war.
The analysis of pfmdr1 haplotypes in Angola revealed
the YEYSNVD and NEYSNVD haplotypes, which were
already observed in isolates from other African countries
[26] and were also detected in Asia [32]. Although previ-
ous studies performed with Angolan samples only
reported 2 mutations - 86Y for pfmdr1 gene and 76T for
pfcrt gene - the frequencies informed for both genes are
in accordance with our findings [16,17].
It is important to notice that for the pfmdr1 gene, asso-
ciations of polymorphisms with CQ sensitivity are less
straightforward than for pfcrt. Mutations in pfmdr1 also
impact on responses to other drugs. Indeed, the same
mutations that apparently decrease sensitivity to CQ,
amodiaquine, and quinine may increase sensitivity to
some other drugs, including mefloquine and halofantrine
[33]. Considering this complexity, the selective pressures
that led to common pfmdr1  haplotypes in Angola are
uncertain.
Of interest, pfcrt and pfmdr1 haplotypes also impact on
sensitivity to amodiaquine. In particular, the SagtVMNT
Table 1: Haplotypes for pfcrt identified in Angola.





CVIET 13 (12.7) 3 6.28 - 19.22
StctVMNT 58 (56.9) 2 47.25 - 66.47
CVMNT 4 (3.9) 1 0.15 - 7.69
CVMNK 3 (2.9) 0 0 - 6.22
CVINT 2 (2) 2 0 - 4.65
CVMDT 3 (2.9) 2 0 - 6.22
Mixed-type (n = 19)
C/S V M/I NT 3 (2.9) 3 0 - 6.22
C/S V M/I N/D T 2 (2) 4 0 - 4.65
C/S V M/I N/E T 1 (1) 4 0 - 2.89
C/S VIET 1 (1) 4 0 - 2.89
C/S VMNT 11 (10.8) 2 4.76 - 16.8
CVM N/D T 1 (1) 2 0 - 2.89
The haplotypes were constructed considering codon positions 72-76. The 95% confidence interval was calculated by Dimension Research 
calculator (http://www.dimensionresearch.com/resources/resources_overview.html).Gama et al. Malaria Journal 2010, 9:174
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haplotype has been associated with decreased amodi-
aquine sensitivity compared to other haplotypes also con-
taining the K76T  mutation [12,26,34], and the pfmdr1
N86Y mutation mediated decreased in vitro sensitivity to
amodiaquine [33], and was selected by prior amodiaquine
therapy [35]. In this context, the 57% prevalence of the
StctVMNT haplotype and 66% prevalence of pfmdr1 86Y
might suggest widespread resistance to amodiaquine in
Angola.
Conclusions
The high prevalence of the pfcrt SVMNT haplotype and
the  pfmdr1  86Y  SNP confirm high-level chloroquine
resistance and might suggest reduced efficacy of amodi-
aquine in Angola. Further in vitro studies must be con-
ducted to evaluate the influence of pfcrt  SVMNT
haplotype to artesunate and amodiaquine sensitivity, for
better conclusive data.
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